Biological therapy: a new age of cancer treatment
Keywords:
Biological Research, Biological Therapy, Medicine, BiomedicalAbstract
Cancer is an important reason causing death in almost countries. So cancer studies become as interesting research field. Many research groups approached cancer treatment with some different strategies. To date, there are four main strategies used in preclinical and clinical treatment included surgery, chemotherapy, radiation therapy, and biological therapy. In some indications, doctors combined them to make combinatorial therapies. In recent years, biological therapies become a promising therapy, especially in invasive cancer. Biological agents formed the targeting therapies that in principle only cancer cells effected by drugs. Biological therapies as monoclonal antibodies, immune cells based immunotherapies showed that the treatment efficiency in some cancers, in recent years. Biomedical Research and Therapy is developed basing on the progress in research and application of biology, biotechnology in disease treatment that included cancer. So that, in this year, Biomedical Research and Therapy will have a special issue with the theme “Biological therapy for cancer treatment”. We will invite some of the leaders in this field to critically review this issue. We expect that this issue will be of great interest for developing the novel approaches and innovations for cancer treatment.
References
Amato, R.J., Shetty, A., Lu, Y., Ellis, P.R., Mohlere, V., Carnahan, N., and Low, P.S. (2014). A Phase I/Ib Study of Folate Immune (EC90 Vaccine Administered With GPI-0100 Adjuvant Followed by EC17) With Interferon-alpha and Interleukin-2 in Patients With Renal Cell Carcinoma. Journal of immunotherapy (Hagerstown, Md : 1997) 37, 237–244.PubMedCrossRef
Aranda, F., Vacchelli, E., Eggermont, A., Galon, J., Sautes-Fridman, C., Tartour, E., Zitvogel, L., Kroemer, G., and Galluzzi, L. (2013). Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2, e26621.
Baron, J.M., Boster, B.L., and Barnett, C.M. (2014). Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Becouarn, Y., Cany, L., Pulido, M., Beyssac, R., Texereau, P., Le Morvan, V., Bechade, D., Brunet, R., Aitouferoukh, S., Lalet, C., et al. (2014). FOLFIRI(R) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC research notes 7, 260.
Bell, J., and McFadden, G. (2014). Viruses for tumor therapy. Cell host & microbe 15, 260–265.CrossRef
Brenner, M.K., Gottschalk, S., Leen, A.M., and Vera, J.F. (2013). Is cancer gene therapy an empty suit? The lancet oncology 14, e447– 456.PubMedCrossRef
Brower, V. (2010). Approval of provenge seen as first step for cancer treatment vaccines. Journal of the National Cancer Institute 102, 1108–1110.PubMedCrossRef
Cheung, M.C., Maceachern, J.A., Haynes, A.E., Meyer, R.M., and Imrie, K. (2009). I-Tositumomab in lymphoma. Current oncology (Toronto, Ont) 16, 32–47.
Cho-Chung, Y.S. (2005). DNA drug design for cancer therapy. Current pharmaceutical design 11, 2811–2823.PubMedCrossRef
Della Vittoria Scarpati, G., Fusciello, C., Perri, F., Sabbatino, F., Ferrone, S., Carlomagno, C., and Pepe, S. (2014). Ipilimumab in the treatment of metastatic melanoma: management of adverse events. OncoTargets and therapy 7, 203–209.PubMedCentralPubMedCrossRef
Duggal, R., Minev, B., Geissinger, U., Wang, H., Chen, N.G., Koka, P.S., and Szalay, A.A. (2013). Biotherapeutic approaches to target cancer stem cells. Journal of stem cells 8, 135–149.PubMed
Frankfurt, O., Ma, S., Gordon, L., Winter, J.N., Horowitz, J., Rademaker, A., Weitner, B.B., Peterson, L.C., Altman, J.K., Tallman, M.S., et al. (2014). A Phase II Study of Alemtuzumab-Rituximab Therapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Short and Long-term Outcomes. Leukemia & lymphoma.
Glassman, P.M., and Balthasar, J.P. (2014). Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer biology & medicine 11, 20–33.
Hohloch, K., Zinzani, P.L., Linkesch, W., Jurczak, W., Deptala, A., Lorsbach, M., Windemuth-Kiesselbach, C., Wulf, G.G., and Truemper, L.H. (2011). Radioimmunotherapy with (90)Yibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network. Bone marrow transplantation 46, 901–903.PubMedCrossRef
Johnston, J.B., Navaratnam, S., Pitz, M.W., Maniate, J.M., Wiechec, E., Baust, H., Gingerich, J., Skliris, G.P., Murphy, L.C., and Los, M. (2006). Targeting the EGFR pathway for cancer therapy. Current medicinal chemistry 13, 3483–3492.PubMedCrossRef
Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497.PubMedCrossRef
Lane, D.P., Brown, C.J., Verma, C., and Cheok, C.F. (2011). New insights into p53 based therapy. Discovery medicine 12, 107–117.PubMed
Lu, W., Zheng, S., Li, X.F., Huang, J.J., Zheng, X., and Li, Z. (2004). Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World journal of gastroenterology : WJG 10, 3634–3638.PubMed
Malecki, M. (2012). Frontiers in Suicide Gene Therapy of Cancer. Journal of genetic syndrome & gene therapy 2012.
Qian, X., Wang, X., and Jin, H. (2014). Cell Transfer Therapy for Cancer: Past, Present, and Future. Journal of immunology research 2014, 525913.
Russell, S.J., Peng, K.W., and Bell, J.C. (2012). Oncolytic virotherapy. Nature biotechnology 30, 658–670.PubMedCrossRef
Shibata, M.A., Shibata, E., Morimoto, J., and Harada-Shiba, M. (2013). Therapy with siRNA for Vegf-c but not for Vegf-d suppresses wide-spectrum organ metastasis in an immunocompetent xenograft model of metastatic mammary cancer. Anticancer research 33, 4237–4247.PubMed
Sutlu, T., and Alici, E. (2009). Natural killer cell-based immunotherapy in cancer: current insights and future prospects. Journal of internal medicine 266, 154–181.PubMedCrossRef
Szarewski, A. (2012). Cervarix(R): a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert review of vaccines 11, 645–657.PubMedCrossRef
Tu, L.C., Foltz, G., Lin, E., Hood, L., and Tian, Q. (2009). Targeting stem cells-clinical implications for cancer therapy. Current stem cell research & therapy 4, 147–153.CrossRef
Yang, T., Rycaj, K., Liu, Z., and Tang, D.G. (2014). Cancer Stem Cells: Constantly Evolving and Functionally Heterogeneous Therapeutic Targets. Cancer research.
Downloads
Published
Issue
Section
License
Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
